Indacaterol improves daily physical activity in patients with chronic obstructive pulmonary disease.
Indacaterol improves daily physical activity in patients with chronic obstructive pulmonary disease.
复制标题
DOI：
10.2147/copd.s38548
复制
发表时间：
2013
影响因子：
2.8
通讯作者：
Taguchi O
中科院分区：
文献类型：
--
作者：
Hataji O;Naito M;Ito K;Watanabe F;Gabazza EC;Taguchi O
目前治疗慢性阻塞性肺疾病（COPD）的主要方法是长效支气管扩张剂。迄今为止，β2激动剂吲达卡特罗对COPD患者日常生活活动的影响尚不清楚。本研究的目的是评估因达卡特罗对慢性阻塞性肺病患者日常生活活动的影响。在这项非随机开放标签的研究中，23名COPD患者被要求携带加速度计4周，不使用因达卡特罗治疗，然后再使用4周，同时使用因达卡特罗治疗。与基线数据相比，所有COPD患者在接受吲哚卡特罗治疗后的步数、中等或更高强度体力活动的持续时间和能量消耗显著增加；吲哚卡特罗治疗后，代谢当量也显著增加。这项研究提供了早期证据，表明吲哚卡特罗可以改善慢性阻塞性肺病患者的日常体力活动。
The current mainstay of therapy for chronic obstructive pulmonary disease (COPD) is long-acting bronchodilators. To date, the effect of indacaterol, a β2-agonist, on activities of daily living in COPD patients is not well understood. The aim of this study was to evaluate the efficacy of indacaterol with regard to activities of daily living in patients with COPD. In this nonrandomized open-label study, 23 patients with COPD were instructed to carry an accelerometer for 4 weeks without indacaterol therapy and then for another period of 4 weeks while receiving indacaterol therapy. The number of steps, duration of moderate or greater physical activity, and energy expenditure were significantly increased after treatment with indacaterol compared with baseline data in all patients with COPD; the metabolic equivalent of task was also significantly enhanced after treatment with indacaterol. This study provides early evidence that indacaterol improves daily physical activity in patients with COPD.